NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference

July 18, 2024

https://www.globenewswire.com/news-release/2024/07/18/2915247/0/en/NKGen-Biotech-to-Present-New-Positive-SNK01-Clinical-Trial-Biomarker-Data-at-the-2024-Alzheimer-s-Association-International-Conference.html

SANTA ANA, Calif., July 18, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq:NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that it will present new biomarker data on SNK01 (autologous non-genetically modified NK cell therapy) in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Association International Conference (“AAIC”) to be held in Philadelphia, PA at the Pennsylvania Convention Center and online from July 28 – August 1, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.